擅長領域：?

執業經歷： 職 稱：副研究員 　　職 務：藥學部主任助理 　　院 區：東院 　　科 室：藥劑科 　　醫療專長：自獲得第一個上海市教委優秀青年教師科學基金開始(2009年)，將研究集中具有用藥復雜、社會負擔重的疾病為研究對象，以運籌統計和臨床決策為研究手段，以評價和比較不同治療藥物的成本及效果效用為目標開展工作。 　　教育經歷 　　2013/09 – 2014/09，多倫多大學Leslie Dan藥學院與多倫多大學附屬總醫院(學習) 　　2005/09 – 2008/06，上海交通大學，博士 　　2002/09 – 2005/06，中國科學院上海藥物研究所，碩士， 　　1997/09 – 2002/06，南京醫科大學 本科 　　論文著作 　　1.期刊論文(SCI收錄第一作者/通訊作者)： 　　[1]. Wu B, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W: Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012, 7(3):e32530. (IF = 3.73) 　　[2]. Wu B, Chen H, Shen J, Ye M: Cost-Effectiveness of Adding Rh-Endostatin to First-Line Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer in China. Clin Ther 2011, 33(10):1446-1455. (IF = 2.23) 　　[3]. Wu B, Ye M, Chen H, Shen JF: Costs of Trastuzumab in Combination With Chemotherapy for HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: An Economic Evaluation in the Chinese Context. Clin Ther 2012, 34(2):468-479. (IF = 2.23) 　　[4]. Wu B, Miao Y, Bai Y, Ye M, Xu Y, Chen H, Shen J, Qiu Y: Subgroup economic analysis for glioblastoma in a health resource-limited setting. PLoS One 2012, 7(4):e34588. (IF = 3.73) 　　[5]. Wu B, Li T, Chen H, Shen J: Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis. Value in Health 2010, 13(5):592-600. (IF = 2.191) 　　[6]. Wu B, Wilson A, Wang F-F, Wang S-L, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012; 7(10): e47373. (IF = 3.73) 　　[7]. Y. Bai, M. Ye, H. Cao, X. Ma, Y. Xu and Wu B *. Economic evaluation of radiotherapy for early breast cancer after breast-conserving surgery in a health resource-limited setting, Breast cancer research and treatment 136 (2012), pp. 547-557. (Corresponding author) (IF = 4.469) 　　[8]. Wu B, J. Shen and H. Cheng, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China, BMC Health Serv Res 12 (2012), p. 385. (IF = 1.773) 　　[9]. J. Zhu, T. Li, X. Wang, M. Ye, J. Cai, Y. Xu and Wu B *. Gene-guided Gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive Non-small cell lung cancer: an economic analysis. BMC Cancer 2013, 13:39. (Corresponding author) (IF = 3.333) 　　[10]. Ben-Juan Wei, Yi-Jun Chen, Li Yu , Wu B. Periodontal Disease and Risk of Preeclampsia: A Meta-Analysis of Observational Studies. PLoS One. 2013. Doi:10.1371/journal.pone.0070901. (IF = 3.73) 　　[11]. Wu B, Kun L, Liu X, He B: Cost-Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2013. 2013 Sep 19. [Epub ahead of print]. PMID: 24048510 (IF = 2.673) 　　獲得榮譽 　　① 吳斌,林厚文, Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B, 中國藥學會，優秀論文二等獎，2013.11 　　② 吳斌,葉明, Initial Chemotherapy with or without Maintenance Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: An Economic Decision Analysis, 中國藥學會，優秀論文二等獎，2012.11 　　③ 吳斌,呂良敬, Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china, 中華醫學會，風濕病2012年會優秀論文三等獎, 2012.5 　　④ 吳斌, 類風濕關節炎患者使用生物制劑治療的經濟學研究, 上海市藥學會，醫院藥學2012年會優秀論文三等獎, 2012.5 　　⑤ 吳斌, Subgroup economic analysis for glioblastoma in a health resource-limited setting, 上海市藥學會，醫院藥學2010年會優秀論文一等獎，2010.11 　　⑥ 吳斌, 中國乙肝患者使用口服核苷類似物治療的藥物經濟學研究, 上海交通大學醫學院，醫院藥學2010年會優秀論文一等獎, 2010.12 　　⑦ 吳斌,邱永明, 腦膠質瘤治療的藥物經濟學決策路徑研究, 中華醫學會，國際神經外科2010年會優秀論文三等獎, 2010.9 　　⑧ 吳斌,沈金芳, Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis, 中國藥學會，優秀論文三等獎，2012.11 詳細介紹